MARKET DEFINITION

Treatments for flea invasions in human or animal populations are known as flea treatments. They can eliminate or kill the fleas themselves as well as alleviate the discomfort brought on by the bites. Anti-itch lotions, typically containing antihistamines or hydrocortisone, can be used to alleviate the irritation brought on by flea bites. Although, calamine lotion works well for itching. The recipient (pet) level of contemporary flea control is approached by utilizing integrated pest management (IPM) procedures. IPM is accomplished by using two distinct chemicals to target fleas at least twice during their different life stages. This is commonly accomplished by killing adult fleas with an adulticide and stopping the development of juvenile stages with an insect growth regulator (IGR) or insect development inhibitor (IDI) like methoprene or lufenuron.

MARKET DYNAMICS

One of the major factors driving the market's growth is the increasing understanding of viruses, as well as an increase in the number of pets. Furthermore, one of the primary influencing causes for a flea item company is the moving concerns of pet owners to get adequate healthcare for their pets. The expanding awareness of the viruses that are transmitted by fleas is also fueling the market for flea products. In addition, Tick and flea-borne animal diseases have considerably grown over the past few years. The ectoparasites, which also induce allergy symptoms and infections, spread a wide range of illnesses, including black plague, murine cholera, ehrlichiosis, rocky mountain speckled fever, Ringworm, tularemia, and anaplasmosis which is giving lucrative growth opportunities for the market. However, fostering discussion on the negative impacts of flea products hinders the market growth.

REPORT SCOPE

The report titled “Global Flea Products Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Flea Products market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Flea Products market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Flea Products Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

GEOGRAPHICAL OVERVIEW

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

MARKET SEGMENTATION  

The Global Flea Products Market is segmented based on Type, Method, Distribution Channel, and region. Based on Type, the market has been segmented into Oral Pill, Spray, Spot On, Powder, Shampoo, Collar, Chewable, and Others, whereas based on Method, the market comprises Internal and External. Based on Distribution Channel, the market has been segmented into Online and Offline.

COMPETITION LANDSCAPE

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Flea Products market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Flea Products market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Flea Products market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Flea Products industry in the past three years.

Key players in the Global Flea Products Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

• Boehringer Ingelheim
• Central Garden & Pet Company
• Ceva
• Ecto Development Corporation
• Elanco
• Laboratoires Francodex
• Merck Inc. (Intervet Inc.)
• Professional Pet Products Inc.
• Sergeant's Pet Care Products Inc.
• The Hartz Mountain Corporation
• Virbac
• Zoetis Inc.

COVID-19 IMPACT ANALYSIS ON GLOBAL FLEA PRODUCTS MARKET

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED

1. What is the current size of the global Flea Products market?
2. What will be the growth rate of the market over the forecast period?
3. Who are the key manufacturers/vendors in the Flea Products market space?
4. What are the major market opportunities and market risks faced by the market?
5. What is the impact of COVID-19 on the market?
6. What are the revenue, sales, and price analysis of the top manufacturers in this market?
7. What are the key outcomes of Porter's five forces model?
8. Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:

• The report offers comprehensive data on the Flea Products market elaborating on the current state and future growth prospects both globally and regionally
• It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth
• The report offers deep-dive insights into each market segment and critical factors responsible for its growth
• The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position
• The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions
• Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope
• The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

 
Chapter 1. Executive Summary
1.1. Market Outlook
1.2. Market Segment Outlook
1.3. Geography Outlook
1.4. Absolute $ Opportunity
 
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Scope, Definition, and Assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary Data Mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
 
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key Trends
3.2.1. Application Trends
3.2.2. End-user Trends
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Impact Analysis of Market Drivers
3.3.2. Market Restraints
3.3.2.1. Impact Analysis of Market Restraints
3.3.3. Market Opportunities
3.3.3.1. Impact Analysis of Market Opportunities
3.3.4. Market Challenges
3.3.4.1. Impact Analysis of Market Challenges
3.4. Porter’s Five Forces’ Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrant
3.4.4. Threat of Substitutes
3.4.5. Competitive Rivalry
3.5. Value Chain Analysis: Global Gemcitabine HCl Market
3.6. COVID-19 Impact Assessment in Gemcitabine HCl Market
3.6.1. Impact Assessment on Global Gemcitabine HCl Market
3.6.2. Market Trends and Opportunities in the Covid-19 Landscape
 
Chapter 4. Global Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
4.1. Global Gemcitabine HCl Market Share, By Application, 2017 - 2028 (USD Million)
4.1.1. Pancreatic Cancer
4.1.2. Breast Cancer
4.1.3. Ovarian Cancer
4.1.4. Non-small Cell Lung Carcinoma (NSCLC)
4.1.5. Others
 
Chapter 5. Global Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
5.1. Global Gemcitabine HCl Market Share, By End-user, 2017 - 2028 (USD Million)
5.1.1. Hospitals
5.1.2. Cancer Centers
5.1.3. Others
 
Chapter 6. Global Gemcitabine HCl Market Overview, By Geography, 2017 - 2028 (USD Million)
6.1. Global Gemcitabine HCl Market Share, By Geography, 2017 - 2028 (USD Million)
6.1.1. Market End-user and Projections, by Countries, 2017 - 2028 (USD Million)
6.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)
 
Chapter 7. North America Gemcitabine HCl Market Overview, By Countries, 2017 - 2028 (USD Million)
7.1. North America Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
7.1.1. Market End-user and projections, 2017 - 2028 (USD Million)
7.1.2. North America Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
7.1.3. North America Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
7.2. North America Gemcitabine HCl Market Overview, By Countries, 2017 - 2028 (USD Million)
7.2.1. U.S. Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
7.2.1.1. U.S. Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
7.2.1.2. U.S. Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
7.2.2. Canada Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
7.2.2.1. Canada Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
7.2.2.2. Canada Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
7.2.3. Mexico Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
7.2.3.1. Mexico Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
7.2.3.2. Mexico Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
 
Chapter 8. Europe Gemcitabine HCl Market Overview, By Countries, 2017 - 2028 (USD Million)
8.1. Europe Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
8.1.1. Market End-user and projections, 2017 - 2028 (USD Million)
8.1.2. Europe Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
8.1.3. Europe Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2. Europe Gemcitabine HCl Market Overview, By Countries, 2017 - 2028 (USD Million)
8.2.1. Germany Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
8.2.1.1. Germany Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
8.2.1.2. Germany Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.2. France Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
8.2.2.1. France Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
8.2.2.2. France Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.3. UK Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
8.2.3.1. UK Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
8.2.3.2. UK Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.4. Italy Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
8.2.4.1. Italy Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
8.2.4.2. Italy Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.5. Spain Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
8.2.5.1. Spain Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
8.2.5.2. Spain Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.6. NORDIC Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
8.2.6.1. NORDIC Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
8.2.6.2. NORDIC Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.7. Russia and CIS Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
8.2.7.1. Russia and CIS Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
8.2.7.2. Russia and CIS Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
8.2.8. Rest of Europe Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
8.2.8.1. Rest of Europe Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
8.2.8.2. Rest of Europe Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
 
Chapter 9. Asia Pacific Gemcitabine HCl Market Overview, By Countries, 2017 - 2028 (USD Million)
9.1. Asia Pacific Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
9.1.1. Market End-user and projections, 2017 - 2028 (USD Million)
9.1.2. Asia Pacific Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
9.1.3. Asia Pacific Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2. Asia Pacific Gemcitabine HCl Market Overview, By Countries, 2017 - 2028 (USD Million)
9.2.1. India Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
9.2.1.1. India Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
9.2.1.2. India Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.2. China Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
9.2.2.1. China Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
9.2.2.2. China Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.3. Japan Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
9.2.3.1. Japan Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
9.2.3.2. Japan Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.4. ASEAN Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
9.2.4.1. ASEAN Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
9.2.4.2. ASEAN Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.5. South Korea Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
9.2.5.1. South Korea Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
9.2.5.2. South Korea Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.6. Australia Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
9.2.6.1. Australia Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
9.2.6.2. Australia Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
9.2.7. Rest of Asia Pacific Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
9.2.7.1. Rest of Asia Pacific Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
9.2.7.2. Rest of Asia Pacific Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
 
Chapter 10. South America Gemcitabine HCl Market Overview, By Countries, 2017 - 2028 (USD Million)
10.1. South America Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
10.1.1. Market End-user and projections, 2017 - 2028 (USD Million)
10.1.2. South America Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
10.1.3. South America Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2. South America Gemcitabine HCl Market Overview, By Countries, 2017 - 2028 (USD Million)
10.2.1. Brazil Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
10.2.1.1. Brazil Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.1.2. Brazil Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2.2. Argentina Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
10.2.2.1. Argentina Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.2.2. Argentina Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
10.2.3. Rest of South America Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
10.2.3.1. Rest of South America Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
10.2.3.2. Rest of South America Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
 
Chapter 11. Middle East & Africa Gemcitabine HCl Market Overview, By Countries, 2017 - 2028 (USD Million)
11.1. Middle East & Africa Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
11.1.1. Market End-user and projections, 2017 - 2028 (USD Million)
11.1.2. Middle East & Africa Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
11.1.3. Middle East & Africa Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
11.2. Middle East & Africa Gemcitabine HCl Market Overview, By Countries, 2017 - 2028 (USD Million)
11.2.1. GCC Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
11.2.1.1. GCC Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.1.2. GCC Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
11.2.2. South Africa Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
11.2.2.1. South Africa Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.2.2. South Africa Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
11.2.3. Rest of Middle East & Africa Gemcitabine HCl Market Overview, 2017 - 2028 (USD Million)
11.2.3.1. Rest of Middle East & Africa Gemcitabine HCl Market Overview, By Application, 2017 - 2028 (USD Million)
11.2.3.2. Rest of Middle East & Africa Gemcitabine HCl Market Overview, By End-user, 2017 - 2028 (USD Million)
 
Chapter 12. Competitive Landscape
12.1. Competitive Environment, 2021
12.2. Strategic Framework
12.2.1. Partnership/Collaborations/Agreement
12.2.2. Expansion
12.2.3. Mergers & Acquisitions
12.2.4. New Product Development
 
Chapter 13. Key Vendor Analysis
13.1. Accord Healthcare
13.1.1. Business Overview
13.1.2. Product Benchmarking
13.1.3. Financial Data
13.1.4. Strategic Overview
13.1.5. Key Developments
13.1.6. SWOT Analysis
13.2. Teva Pharmaceutical Industries Ltd.
13.2.1. Business Overview
13.2.2. Product Benchmarking
13.2.3. Financial Data
13.2.4. Strategic Overview
13.2.5. Key Developments
13.2.6. SWOT Analysis
13.3. Dr. Reddy's Laboratories Ltd.
13.3.1. Business Overview
13.3.2. Product Benchmarking
13.3.3. Financial Data
13.3.4. Strategic Overview
13.3.5. Key Developments
13.3.6. SWOT Analysis
13.4. Sun Pharmaceutical Industries Ltd.
13.4.1. Business Overview
13.4.2. Product Benchmarking
13.4.3. Financial Data
13.4.4. Strategic Overview
13.4.5. Key Developments
13.4.6. SWOT Analysis
13.5. Mylan N.V.
13.5.1. Business Overview
13.5.2. Product Benchmarking
13.5.3. Financial Data
13.5.4. Strategic Overview
13.5.5. Key Developments
13.5.6. SWOT Analysis
13.6. Fresenius SE & Co. KGaA
13.6.1. Business Overview
13.6.2. Product Benchmarking
13.6.3. Financial Data
13.6.4. Strategic Overview
13.6.5. Key Developments
13.6.6. SWOT Analysis
13.7. Pfizer, Inc.
13.7.1. Business Overview
13.7.2. Product Benchmarking
13.7.3. Financial Data
13.7.4. Strategic Overview
13.7.5. Key Developments
13.7.6. SWOT Analysis
13.8. Eli Lilly and Company
13.8.1. Business Overview
13.8.2. Product Benchmarking
13.8.3. Financial Data
13.8.4. Strategic Overview
13.8.5. Key Developments
13.8.6. SWOT Analysis
13.9. Ingenus Pharmaceuticals, LLC.
13.9.1. Business Overview
13.9.2. Product Benchmarking
13.9.3. Financial Data
13.9.4. Strategic Overview
13.9.5. Key Developments
13.9.6. SWOT Analysis
13.10. Cornerstone Pharmaceuticals, Inc.
13.10.1. Business Overview
13.10.2. Product Benchmarking
13.10.3. Financial Data
13.10.4. Strategic Overview
13.10.5. Key Developments
13.10.6. SWOT Analysis
13.11. ADC Therapeutics SA
13.11.1. Business Overview
13.11.2. Product Benchmarking
13.11.3. Financial Data
13.11.4. Strategic Overview
13.11.5. Key Developments
13.11.6. SWOT Analysis
13.12. Hikma Pharmaceuticals plc
13.12.1. Business Overview
13.12.2. Product Benchmarking
13.12.3. Financial Data
13.12.4. Strategic Overview
13.12.5. Key Developments
13.12.6. SWOT Analysis
 
Chapter 14. Future Outlook of the Market